Clinical Trial Update: Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing TIVA and VIMA on GSK-3beta content in leukocytes of patients undergoing on-pump surgery has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Synthase Kinase 3

Drugs mentioned

• TIVA
• VIMA

Snippet

Sponsor: Moscow Regional Research and Clinical Institute (MONIKI) | Conditions: Glycogen Synthase Kinase 3 | Phase 4 | Status: TERMINATED